Zolgensma – Talk Bio

Actionable Insights Powered by AI

FDA Approves Novartis’ Itvisma: Expanding Gene Therapy to Older Spinal Muscular Atrophy Patients

2 weeks ago talkbio0Tagged Adult, Approved, gene therapy, intrathecal formulation, Itvisma, Novartis, older children, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis; FDA approval; Itvisma; Zolgensma; Spinal Muscular Atrophy (SMA); Gene Therapy; Older Children; Adults; Intrathecal Formulation

Biogen Ushers Spinraza Follow-Up (Salanersen) Into Pivotal SMA Studies

6 months ago talkbio0Tagged Antistreptolysin O, Biogen, Clinical Trials, motor milestones, Nerve Degeneration, Novartis, Pediatric brand name, Phase III, salanersen, Spinal Muscular Atrophy, Spinraza, Zolgensma

Biogen; SMA; Spinraza; salanersen; Phase III; clinical trials; neurodegeneration; motor milestones; pediatric; Novartis Zolgensma; ASO therapy

RegenXBio Secures Up to $250 Million by Monetizing Royalties from Zolgensma and Two Gene Therapies

7 months ago talkbio0Tagged gene therapy, HealthCare Royalty, milestone payments, non-dilutive financing, Regenxbio, RGX-111, RGX-121, royalty monetization, Zolgensma

RegenXBio; Zolgensma; gene therapy; royalty monetization; HealthCare Royalty; RGX-121; RGX-111; non-dilutive financing; biotech; milestone payments

Novartis Prepares to File Intrathecal Zolgensma for Older SMA Patients by Mid-2025

9 months ago talkbio0Tagged gene therapy, intrathecal delivery, older, Spinal Muscular Atrophy, Zolgensma

Zolgensma, intrathecal delivery, spinal muscular atrophy, gene therapy, older patients

Novartis Achieves Pivotal Trial Success for Intrathecal Zolgensma in Older SMA Patients After FDA Delay

11 months ago talkbio0Tagged Approved, intrathecal formulation, Novartis, older, Phase 3 trial, Spinal Muscular Atrophy, United States Food and Drug Administration, Zolgensma

Novartis, Zolgensma, Intrathecal formulation, Spinal muscular atrophy (SMA), FDA approval, Pivotal phase 3 trial, Older SMA patients